This article needs additional citations for verification. (March 2015) |
Clinical data | |
---|---|
Trade names | Usevir, Brovavir |
Other names | BV-araU, Bromovinyl araU, 5-Bromovinyl-araU, 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione |
Routes of administration | Oral |
ATC code |
|
Pharmacokinetic data | |
Metabolism | Viral thymidine kinase |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H13BrN2O6 |
Molar mass | 349.137 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Sorivudine (INN), is a nucleoside analogue antiviral drug, marketed under trade names such as Usevir (Nippon Shoji, Eisai) and Brovavir (BMS). It is used for the treatment of varicella zoster virus infections.[1]